#DMARDs
Rheumatoid arthritis:
Rheumatoid arthritis (RA) is a common multisystem autoimmune disease. About 0.5% to 1% of the population in Canada lives with RA.
Learn more ➡️ www.cmaj.ca/lookup/doi/10.1503/cmaj.260500
November 17, 2026 at 3:37 PM
From ACR '26: Combining individualized depression pharmacotherapy with olokizumab and conventional synthetic DMARDs demonstrates superior clinical improvement compared with conventional therapy alone. www.empr.com/reports/olok...
Olokizumab Plus Psychiatric Treatment Boosts Response in Rheumatoid Arthritis
Olokizumab combined with depression therapy improves clinical response and remission rates among patients with rheumatoid arthritis and depression.
www.empr.com
November 11, 2026 at 8:49 PM
Vagal nerve stimuation in RA:
I think when you implant a machine in your neck, you have expectations, even if not immunosuppressive

24mo follow-up RESET-RA VNS device
refractory RA pts
but is ACR20 60% good enough?
(you can add DMARDs on top, though)

ABST1426 #ACR26 RheumNow (on X)
November 9, 2026 at 3:30 PM
Gradual dose reduction of biologic & targeted #DMARDs is noninferior to continued standard-dose treatment for maintaining low disease activity in rheumatoid #arthritis patients.

@acr-journals.bsky.social

https://www.rheumatologyadvisor.com/news/dmard-tapering-rheumatoid-arthritis-disease-control/
Biologic, Targeted Synthetic DMARD Tapering Maintains Disease Control in RA
Reducing doses of biologic and targeted synthetic DMARDs effectively maintains low disease activity in patients with rheumatoid arthritis.
www.rheumatologyadvisor.com
November 3, 2026 at 9:21 PM
Characterizing a large, international cohort of childhood-onset Takayasu arteritis showed treatment has evolved over time from conventional DMARDs to biologics; however, patient outcomes have remained largely unchanged

ACR Open Rheumatology
doi.org/10.1002/acr2...
November 4, 2026 at 1:07 PM
Long term F/U of 80 systemic sclerosis pts Rx w/ autologous HSCT. W/ Med. 9.2 yrs F/U progression-free survival = 81%, 72% @5 yrs, & 60% @10 yrs. 18 pts died; death due to HSCT in 6%, SSc progression in 11%, CA in 2 (3%), serious infx 2 (3%), 34 (43%) maintained remission - no DMARDs buff.ly/ZFy3MkO
Long-term evaluation of the effectiveness and safety of autologous haematopoietic stem-cell transplantation for systemic sclerosis (NISSC1-LTE): a cohort study
This study provides long-term follow-up data after autologous HSCT in patients with systemic sclerosis allowing robust assessment of response rate, late complications, and sustained treatment…
buff.ly
November 2, 2026 at 4:03 PM
Tx persistence & response in PsA is a problem - influenced by demographics & Dz severity. 815 PsA pts in e Brit Society Rheumatology PsA Registe. @12 mos - 24% MDA, 24% ACR50. Median F/U 31 mos, only 65% still on index Rx. D/C higher w/ PDE4i & poorer baseline activity & PROs buff.ly/8S9nYoz
Predictors of b/tsDMARDs discontinuation and treatment response in psoriatic arthritis: results from the British Society for Rheumatology Psoriatic Arthritis Register (BSR-PsA)
AbstractObjectives. Despite advances in biologic and targeted synthetic DMARDs (b/tsDMARDs), many patients with psoriatic arthritis (PsA) experience subopt
buff.ly
October 30, 2026 at 2:01 PM
レフラ(レフルノミド):免疫系を整える治療薬「レフラ – レフルノミド(Lefra – Leflunomide)」レフラはレフルノミドを有効成分とする、リウマチ治療の医薬品です。関節の腫れや痛みを抑え、つらいリウマチの症状を和らげます。 | WEBシステムの頂点・ケテル東京 レフラ(一般名:レフルノミド/Leflunomide)は、主にリウマチや自己免疫疾患の治療に使用される薬です。特に、関節リウマチの進行を抑えるための疾患修飾性抗リウマチ薬(DMARDs)として広く利用されています。
レフラ(レフルノミド):免疫系を整える治療薬「レフラ - レフルノミド(Lefra - Leflunomide)」レフラはレフルノミドを有効成分とする、リウマチ治療の医薬品です。関節の腫れや痛みを抑え、つらいリウマチの症状を和らげます。 - ケテル東京
レフラ – レフルノミド(Lefra – Leflunomide) 概要 レフラ(一般名:レフルノミド/Leflunomide)は、主にリウマチや自己免疫疾患の治療に使用される薬です。特に、関節リ […]
keter.tokyo
October 28, 2026 at 11:14 PM
JAMA Uveitis review: Uveitis peaks at 20–50 yrs; 41–60% is anterior. ~40 linked to systemic disease (HLA-B27=axSpA). 1st exclude infection (TB, toxo, herpes). Anterior UV: topical steroids. Posterior/pan UV: DMARDs first (MTX remission 52%, MMF 71%); adalimumab if refractory buff.ly/uWveWTw
Uveitis in Adults: A Review
This narrative review summarizes current evidence on the pathophysiology, epidemiology, diagnosis, and treatment of uveitis in adults.
buff.ly
October 26, 2026 at 10:07 PM
Immunosuppressed individuals who received a #COVID19 vaccine and at least 1 booster experienced shorter hospital stays and lower odds of mortality from SARS-CoV-2 infection.

https://www.rheumatologyadvisor.com/news/covid-19-vaccination-outcomes-dmards-biologics/
COVID-19 Vaccination Linked to Lower Mortality, Shorter Hospital Stays in Immunocompromised Patients
COVID-19 vaccination is linked to decreased in-hospital mortality and shorter hospital stays among patients receiving immunomodulatory therapies.
www.rheumatologyadvisor.com
October 20, 2026 at 6:51 PM
Cryptococcus is rare, but twice as likely with JAK inhibitors. Retrospective TriNetX analysis of RA pts (>30k/grp) starting JAKi vs TNFi; JAKi vs non-TNFi; & TNFi vs non-TNF. Crypto seen in <0.2% in all groups; but signif higher HR for JAKi (HR 2.2 & 2.15) buff.ly/t9QJktX
Cryptococcosis After Initiation of Janus Kinase Inhibitors or Biologic DMARDs in Rheumatoid Arthritis: Three Pairwise Active-Comparator Analyses of Propensity Score-Matched TriNetX Cohorts, 2005–2025
Background/Objectives: Comparative safety evidence for cryptococcosis during advanced rheumatoid arthritis (RA) therapy is limited. We compared newly recorded cryptococcosis after initiation of Janus…
buff.ly
October 20, 2026 at 3:00 PM
レフラ(レフルノミド):免疫系を整える治療薬「レフラ – レフルノミド(Lefra – Leflunomide)」レフラはレフルノミドを有効成分とする、リウマチ治療の医薬品です。関節の腫れや痛みを抑え、つらいリウマチの症状を和らげます。 | WEBシステムの頂点・ケテル東京 レフラ(一般名:レフルノミド/Leflunomide)は、主にリウマチや自己免疫疾患の治療に使用される薬です。特に、関節リウマチの進行を抑えるための疾患修飾性抗リウマチ薬(DMARDs)として広く利用されています。
レフラ(レフルノミド):免疫系を整える治療薬「レフラ - レフルノミド(Lefra - Leflunomide)」レフラはレフルノミドを有効成分とする、リウマチ治療の医薬品です。関節の腫れや痛みを抑え、つらいリウマチの症状を和らげます。 - ケテル東京
レフラ &#8211; レフルノミド(Lefra &#8211; Leflunomide) 概要 レフラ(一般名:レフルノミド/Leflunomide)は、主にリウマチや自己免疫疾患の治療に使用される薬です。特に、関節リ [&hellip;]
keter.tokyo
October 16, 2026 at 12:26 AM
Tapering DMARDs in RA in sustained control?

27 publications, 5,262 patients (RCTs): tapering raised flare risk (RR 1.56), withdrawal more (RR 2.23), mainly with biologics. Neither cut adverse events.

Zhang, Xu et al. Clin Transl Sci 2026

https://pubmed.ncbi.nlm.nih.gov/42836514/
#MedSky #RheumSky
October 12, 2026 at 1:03 PM
RESTORE-RA shows that stepwise tapering of b/tsDMARDs in rheumatoid arthritis patients with sustained remission or low disease activity maintained disease control in most patients, supporting individualized dose reduction in clinical practice

Arthritis & Rheumatology
doi.org/10.1002/art....
October 12, 2026 at 12:11 PM
“Results indicated that stopping targeted therapies did not increase COVID-19 vaccine immune responses, but did raise the risk of arthritis flares.”
www.medpagetoday.com/rheumatology...
Stop Arthritis Patients' DMARDs Ahead of COVID Jabs? Trial Brings Clarity
Lingering question from the pandemic now appears settled; the short answer is: don't
www.medpagetoday.com
October 6, 2026 at 12:59 PM
Upadacitinib is now approved in European Union to treat active polyarticular juvenile idiopathic arthritis (pJIA) ages > 2yrs for those not responding to 1+ DMARDs. In the USA, UPA is approved for pJIA & juvenile PsA buff.ly/5zhbQmj
October 3, 2026 at 2:00 PM
The weight is off, the DMARDs are off - now what?

When treatments succeed, we have to plan the next steps. Let’s remember why we started and set new goals for life after the weight change. buff.ly/cAgYuG1
October 2, 2026 at 2:00 PM
October A&R - In This Issue:
•Long-Term Osteoporosis Progression With DMARDs
•Baricitinib Response in Lupus Endotypes
•Molecular Endotypes in SLE: CV Risk and LN Insights
→Journal Club: Ixekizumab + Tirzepatide in PsA with overweight or obesity

acrjournals.onlinelibrary.wiley.com/doi/epdf/10....
October 1, 2026 at 4:02 PM
Upadacitinib is now approved in European Union to treat active polyarticular juvenile idiopathic arthritis (pJIA) ages > 2yrs for those not responding to 1+ DMARDs. In the USA, UPA is approved for pJIA & juvenile PsA buff.ly/5zhbQmj
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis
NORTH CHICAGO, Ill., Sept. 22, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved RINVOQ® (upadacitinib; 15 mg tablet and weight-based 1 mg/mL…
buff.ly
September 28, 2026 at 6:01 PM
This study assessed and evaluated the safety and efficacy of rapid drug desensitization for pediatric patients who had hypersensitivity reactions (HSRs) to chemotherapeutics, monoclonal antibodies, and disease-modifying antirheumatic drugs (DMARDs). Read more: www.annallergy.org/article/S108...
Rapid drug desensitization in pediatric patients
Drug hypersensitivity is often managed by drug desensitization, yet published data remain scarce in children. This study evaluated the safety and efficacy of rapid desensitization to chemotherapeutic ...
www.annallergy.org
September 24, 2026 at 1:47 PM
レフラ(レフルノミド):免疫系を整える治療薬「レフラ – レフルノミド(Lefra – Leflunomide)」レフラはレフルノミドを有効成分とする、リウマチ治療の医薬品です。関節の腫れや痛みを抑え、つらいリウマチの症状を和らげます。 | WEBシステムの頂点・ケテル東京 レフラ(一般名:レフルノミド/Leflunomide)は、主にリウマチや自己免疫疾患の治療に使用される薬です。特に、関節リウマチの進行を抑えるための疾患修飾性抗リウマチ薬(DMARDs)として広く利用されています。
レフラ(レフルノミド):免疫系を整える治療薬「レフラ - レフルノミド(Lefra - Leflunomide)」レフラはレフルノミドを有効成分とする、リウマチ治療の医薬品です。関節の腫れや痛みを抑え、つらいリウマチの症状を和らげます。 - ケテル東京
レフラ &#8211; レフルノミド(Lefra &#8211; Leflunomide) 概要 レフラ(一般名:レフルノミド/Leflunomide)は、主にリウマチや自己免疫疾患の治療に使用される薬です。特に、関節リ [&hellip;]
keter.tokyo
September 25, 2026 at 5:35 AM
Oh there also isn't a single proper medical trial of neurosarc. Nothing double-blind, no gold-standard science. We're just too rare to assemble into a cohort.

Enough signal got through to pump me full of IV steroids, transition to 1mg/kg prednisone, taper those while moving to DMARDS/biologics.
September 15, 2026 at 1:15 PM
Measles Outbreaks Threaten Vulnerable Rheumatic Patients

15 September 2026 (Navroze Bureau) : Ongoing measles outbreaks are creating a particular risk for adults living with autoimmune rheumatic diseases, as declining vaccination coverage can leave immunosuppressed patients vulnerable to a highly…
Measles Outbreaks Threaten Vulnerable Rheumatic Patients
15 September 2026 (Navroze Bureau) : Ongoing measles outbreaks are creating a particular risk for adults living with autoimmune rheumatic diseases, as declining vaccination coverage can leave immunosuppressed patients vulnerable to a highly contagious infection. A recent rheumatology review highlights the challenge faced by patients taking disease-modifying antirheumatic drugs (DMARDs), many of whom cannot simply receive the live-attenuated measles, mumps and rubella (MMR) vaccine while undergoing active immunosuppressive treatment.
navroze.in
September 15, 2026 at 5:50 AM